Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

HIV-1 diversity after a class switch failure.

Kolber MA, Buendia P, Degruttola V, Moore RD.

AIDS Res Hum Retroviruses. 2010 Nov;26(11):1175-80. doi: 10.1089/aid.2010.0069. Epub 2010 Sep 21.

2.

Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort.

Zolfo M, Schapiro JM, Phan V, Koole O, Thai S, Vekemans M, Fransen K, Lynen L.

AIDS Res Hum Retroviruses. 2011 Jul;27(7):727-35. doi: 10.1089/AID.2010.0037. Epub 2010 Nov 23.

PMID:
20854169
3.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
5.

Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.

Agwu A, Lindsey JC, Ferguson K, Zhang H, Spector S, Rudy BJ, Ray SC, Douglas SD, Flynn PM, Persaud D; Pediatric AIDS Clinical Trials Group 381 Study Team.

AIDS Patient Care STDS. 2008 Jul;22(7):545-52. doi: 10.1089/apc.2007.0200.

6.

Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.

Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ; Study 934 Team.

J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):209-21. doi: 10.1097/QAI.0b013e3181b05f7c.

PMID:
19644384
7.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
8.

High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.

Fofana DB, Soulié C, Baldé A, Lambert-Niclot S, Sylla M, Ait-Arkoub Z, Diallo F, Sangaré B, Cissé M, Maïga IA, Fourati S, Koita O, Calvez V, Marcelin AG, Maïga AI.

J Antimicrob Chemother. 2014 Sep;69(9):2531-5. doi: 10.1093/jac/dku153. Epub 2014 May 22.

PMID:
24855120
9.

Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V.

Pediatr Infect Dis J. 2009 Sep;28(9):826-30. doi: 10.1097/INF.0b013e3181a458f9.

PMID:
19654564
10.
11.

Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.

Kandathil AJ, Kannangai R, Verghese VP, Pulimood SA, Rupali P, Sridharan G, Grant P, Pillay D, Abraham OC.

Indian J Med Microbiol. 2009 Jul-Sep;27(3):231-6. doi: 10.4103/0255-0857.53205.

12.

Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA.

Masquelier B, Neau D, Chêne G, Larbère J, Birac V, Ragnaud JM, Fleury HJ.

J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):309-12.

PMID:
11707665
13.

Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.

Bunupuradah T, Suntarattiwong P, Li A, Sirivichayakul S, Pancharoen C, Boonrak P, Puthanakit T, Kerr SJ, Ruxrungtham K, Chotpitayasunondh T, Hirschel B, Ananworanich J; HIV-NAT 013 Study Team.

Int J Infect Dis. 2010 Apr;14(4):e311-6. doi: 10.1016/j.ijid.2009.05.017. Epub 2009 Aug 21.

14.

[Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy].

Brunner J, Seybold U, Gunsenheimer-Bartmeyer B, Hamouda O, Bogner JR; ClinSurv-Studiengemeinschaft (gleichwertiger Beitrag).

Dtsch Med Wochenschr. 2010 Jun;135(23):1166-70. doi: 10.1055/s-0030-1255124. Epub 2010 May 31. German.

PMID:
20514595
15.

Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.

Theys K, Camacho RJ, Gomes P, Vandamme AM, Rhee SY; Portuguese HIV-1 Resistance Study Group.

Clin Microbiol Infect. 2015 Jun;21(6):607.e1-8. doi: 10.1016/j.cmi.2015.02.011. Epub 2015 Feb 19.

16.

Drug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in Mauritania.

Fall-Malick FZ, Tchiakpé E, Ould Soufiane S, Diop-Ndiaye H, Mouhamedoune Baye A, Ould Horma Babana A, Touré Kane C, Lo B, Mboup S.

J Med Virol. 2014 Mar;86(3):404-10. doi: 10.1002/jmv.23860. Epub 2013 Dec 7.

PMID:
24318486
17.

Enfuvirtide (T-20) resistance-related mutations in HIV type 1 subtypes B, C, and F isolates from Brazilian patients failing HAART.

Oliveira AC, Martins AN, Pires AF, Arruda MB, Tanuri A, Pereira HS, Brindeiro RM.

AIDS Res Hum Retroviruses. 2009 Feb;25(2):193-8. doi: 10.1089/aid.2008.0160.

PMID:
19239358
19.

Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.

Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR.

AIDS. 2007 Apr 23;21(7):813-23.

PMID:
17415036
20.

Genetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, Mozambique.

Ismael N, Bila D, Mariani D, Vubil A, Mabunda N, Abreu C, Jani I, Tanuri A.

AIDS Res Hum Retroviruses. 2014 Jun;30(6):603-9. doi: 10.1089/AID.2013.0244. Epub 2013 Dec 21.

Supplemental Content

Support Center